Standout Papers

Efficacy and safety of sunitinib in patients with advanced gastrointesti... 2000 2026 2008 2017 1.9k
  1. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial (2006)
    George D. Demetri, Allan T. van Oosterom et al. The Lancet
  2. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors (2003)
    Michael C. Heinrich, Christopher L. Corless et al. Science
  3. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor (2003)
    Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology
  4. Biology of Gastrointestinal Stromal Tumors (2004)
    Christopher L. Corless, Jonathan A. Fletcher et al. Journal of Clinical Oncology
  5. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor (2000)
    Michael C. Heinrich, Diana Griffith et al. Blood
  6. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants (2005)
    Thomas O’Hare, Denise K. Walters et al. Cancer Research
  7. Gastrointestinal stromal tumour (2007)
    Brian P. Rubin, Michael C. Heinrich et al. The Lancet
  8. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033 (2008)
    Charles D. Blanke, Cathryn Rankin et al. Journal of Clinical Oncology
  9. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT (2008)
    Charles D. Blanke, George D. Demetri et al. Journal of Clinical Oncology
  10. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo (2003)
    Tinya J. Abrams, Sharianne G. Louie et al. Blood
  11. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib (2005)
    Christopher L. Corless, Arin Schroeder et al. Journal of Clinical Oncology
  12. Gastrointestinal stromal tumours: origin and molecular oncology (2011)
    Christopher L. Corless, Christine M. Barnett et al. Nature reviews. Cancer
  13. Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors (2006)
    Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology
  14. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor (2008)
    Michael C. Heinrich, Robert G. Maki et al. Journal of Clinical Oncology
  15. The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status (2004)
    Robert B. West, Christopher L. Corless et al. American Journal Of Pathology
  16. Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group (2008)
    Michael C. Heinrich, Kouros Owzar et al. Journal of Clinical Oncology
  17. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors (2013)
    Juliann Chmielecki, Aimeé M. Crago et al. Nature Genetics
  18. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial (2020)
    Jean‐Yves Blay, César Serrano et al. The Lancet Oncology

Immediate Impact

6 by Nobel laureates 24 from Science/Nature 129 standout
Sub-graph 1 of 17

Citing Papers

Challenges and Opportunities in Cancer Drug Resistance
2020 Standout
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
2017 Standout
26 intermediate papers

Works of Michael C. Heinrich being referenced

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases
2008
STI571: A Paradigm of New Agents for Cancer Therapeutics
2002
and 38 more

Author Peers

Author Last Decade Papers Cites
Michael C. Heinrich 16713 17093 5168 8229 373 31.5k
Christopher L. Corless 14883 16635 1735 9665 318 30.3k
Jonathan A. Fletcher 8303 10823 2005 4408 202 22.9k
Robert G. Maki 7745 17885 1113 5137 377 25.7k
Brian P. Rubin 7150 10841 822 5075 273 18.7k
Margaret von Mehren 8993 10412 1063 4857 282 15.9k
Christopher D.�M. Fletcher 13975 37622 2096 14085 671 64.4k
Jason L. Hornick 2279 11221 428 4978 479 24.0k
Peter Reichardt 5022 8999 607 3764 348 14.6k
Brian Druker 4191 6248 29898 2317 597 54.0k
Yung‐Jue Bang 4423 16587 360 7405 602 36.1k

All Works

Loading papers...

Rankless by CCL
2026